Alprazolam and Suicidal Ideation: A Meta-Analysis of Controlled Trials in the Treatment of Depression
The DOI matches its Crossref record.
Abstract
A meta-analysis of well-controlled studies of alprazolam in depression was performed to assess the possible association of alprazolam and suicidal ideation. Pooled data from 3,217 patients (alprazolam, placebo, and various active-comparative agents) who were enrolled in 22 placebo- and/or active drug-controlled depression studies were retrospectively analyzed to evaluate the emergence, worsening, and improvement of suicidal ideation during treatment with alprazolam, placebo, or other active drugs. Item 3 of the Hamilton Rating Scale for Depression was used to evaluate these events. Neither the risk of emergence nor the risk of worsening of suicidal ideation was significantly different for alprazolam than for placebo; however, alprazolam was significantly superior to placebo in producing improvement of suicidal ideation. There was no significant difference between alprazolam and the active-comparator group in the risk of emergence of suicidal ideation. The risk of worsening of suicidal ideation was significantly less for the active-comparator group (the majority of patients in this group received amitriptyline or imipramine) than for alprazolam, and improvement of suicidal ideation occurred significantly more frequently in that group than in the alprazolam group. Use of alprazolam in depressed patients is not associated with any particular increased risk of suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
The GABA system in anxiety and depression and its therapeutic potential
Möhler, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.040 · Cited by 590
Dysfunctional hippocampal activity affects emotion and cognition in mood disorders
Femenía, T., Gómez-Galán, M., Lindskog, M., & Magara, S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.03.053 · Cited by 143
Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA
McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., McCloud, L., Newman, J. C., Case, D., Rumble, M., & Krystal, A. D. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16030336 · Cited by 139
“ODS Postmarketing safety review drug(s) zaleplon (20-859) - eszopiclone (21-476) - zolpidem (19-908) Event - suicidal ideation and attempts - completed suicides.”
BackgroundThe role of psychopharmacology in suicide prevention
Saunders, K. E. A., & Hawton, K. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000427 · Cited by 34
Metadata
- Authors
- Jonas, J. M., & Hearron, A. E. J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1996-06
- Volume
- 16
- Issue
- 3
- Pages
- 208-211
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2059861694
- Cited by
- 45
- References
- 0
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alprazolam and Suicidal Ideation: A Meta-Analysis of Controlled Trials in the Treatment of Depression. https://app.cochat.ai/papers/10.1097/00004714-199606000-00003
- The paper
- Jonas, J. M., & Hearron, A. E. J. (1996). Alprazolam and Suicidal Ideation: A Meta-Analysis of Controlled Trials in the Treatment of Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199606000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.